Teva Pharmaceutical Industries (TEVA) said Wednesday a phase 3 study of its fremanezumab drug to prevent episodic migraine in patients aged 6 to 17 years showed "statistically significant superior efficacy" compared with placebo.
The drug also showed a favorable safety profile "consistent with that observed in the adult population," the company said.
Teva said it continues to study the impact of fremanezumab on pediatric patients with chronic migraines and its long-term safety.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。